Conduit Pharmaceuticals INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Corvus Capital Ltd. and Andrew Regan have amended their Schedule 13D filing for CDT Equity Inc., reporting increased beneficial ownership to 5.3% and 5.4% respectively, following warrant exercises and open market purchases.
NASDAQ
SCHEDULE: CDT Equity Inc. Sees Major Stake Shift
Mark Taylor and his entities, Prospect Capital and Prospect Finance, significantly increase their stake in CDT Equity Inc. to 43.79% following a strategic acquisition and warrant exercise.
NASDAQ
Corvus Capital Ltd. increased its beneficial ownership in CDT Equity Inc. to 12.2% by acquiring a subsidiary and receiving shares and pre-funded warrants as part of a $7 million settlement.
NASDAQ
Andrew Regan, a director and officer of CDT Equity Inc., significantly increased his beneficial ownership to 13.3% after receiving 1.12 million shares as compensation.
NASDAQ
SCHEDULE: Conduit Pharmaceuticals Updates Ownership, Details Reverse Splits and New Development Agreement
Conduit Pharmaceuticals Inc. has filed an amended Schedule 13D, revealing significant changes in beneficial ownership, detailing two recent reverse stock splits, and announcing a new Joint Development Agreement with related party Manoira Corporation.